

Table S1 miRNAs dysregulated in DLBCL

miRNA name	Cell type	References
has-let-7d	Immunophenotype classified DLBCL cell lines	(34)
	DLBCL tissue samples	(7)
hsa-let-7e	DLBCL tissue samples	(36)
	DLBCL tissue samples	(7)
hsa-let-7g	Immunophenotype classified DLBCL cell lines	(34)
	DLBCL tissue samples	(7)
hsa-mir-106a	DLBCL tissue samples	(36)
	Immunohistochemically classified DLBCL cell lines	(37)
	Tonsillar lymphocytes	(38)
hsa-mir-106b	Tonsillar lymphocytes	(38)
	Immunohistochemically classified DLBCL cell lines	(37)
hsa-mir-143	B-cell lymphoma cell lines	(39)
	DLBCL tissue samples	(23)
hsa-mir-146a	DLBCL samples	(40)
	DLBCL biopsy samples	(41)
hsa-mir-146b	DLBCL tissue samples	(40)
	nodal DLBCL samples	(42)
hsa-mir-150	DLBCL tissue samples	(36)
	DLBCL tissue samples	(23)
	DLBCL biopsy samples	(43)
hsa-mir-155	DLBCL tissue samples	(36)
	DLBCL tissue samples	(40)
	DLBCL tissue samples	(44)
	DLBCL tissue samples	(45)
hsa-mir-15a	DLBCL serum samples	(46)
	Primary extramedullary plasmacytoma (EP) samples	(47)
	DLBCL serum samples	(46)
hsa-mir-16-1	Primary extramedullary plasmacytoma (EP) samples	(47)
	DLBCL tissue samples	(36)
hsa-mir-17	DLBCL tissue samples	(7)
	SUDHL4 cells from DLBCL	(48)
	DLBCL tissue samples	(40)
hsa-mir-182	DLBCL tissue samples	(49)
	DLBCL tissue samples	(49)
hsa-mir-18a	Tonsillar lymphocytes	(38)
	DLBCL tissue samples	(50)
hsa-mir-18b	DLBCL tissue samples	(23)
	Immunohistochemically classified DLBCL cell lines	(37)
hsa-mir-199a	DLBCL tissue samples	(40)
	DLBCL tissue samples	(51)
hsa-mir-19a	DLBCL tissue samples	(7)
	DLBCL tissue samples	(52)
hsa-mir-19b	DLBCL tissue samples	(7)
	DLBCL tissue samples	(52)
hsa-mir-20a	DLBCL tissue samples	(7)
	DLBCL tissue samples	(52)
hsa-mir-21	DLBCL tissue samples	(23)
	DLBCL tissue samples	(53)
hsa-mir-210	DLBCL tissue samples	(36)
	DLBCL tissue samples	(54)
hsa-mir-221	DLBCL tissue samples	(40)
	DLBCL tissue samples	(55)
hsa-mir-24	DLBCL tissue samples	(35)
	Tonsillar lymphocytes	(38)
hsa-mir-30b	DLBCL tissue samples	(40)
	FFPET-derived DLBCL samples	(56)
hsa-mir-320	DLBCL tissue samples	(36)
	nodal DLBCL samples	(42)
hsa-mir-328	DLBCL tissue samples	(36)
	DLBCL tissue samples	(40)
hsa-mir-139	DLBCL tissue samples	(36)
	DLBCL tissue samples	(49)
hsa-mir-34a	DLBCL tissue samples stored in liquid nitrogen	(57)
	Primary Gastric DLBCL tissue samples stored in liquid nitrogen	(58)
hsa-mir-34b	DLBCL tissue samples	(40)
	FFPE DLBCL tissue samples	(59)
hsa-mir-365a	DLBCL tissue samples	(40)
	FFPE DLBCL tissue samples	(60)
hsa-mir-451b	DLBCL tissue samples	(40)
	DLBCL tissue samples of mice	(61)
hsa-mir-485	DLBCL tissue samples	(40)
	Fresh frozen DLBCL tissue	(62)
hsa-mir-9	DLBCL tissue samples	(40)
	DLBCL tissue samples	(23)
hsa-mir-92a	Tonsillar lymphocytes	(38)
	DLBCL tissue samples	(54)
hsa-mir-93	Immunohistochemically classified DLBCL cell lines	(37)
	DLBCL tissue samples	(54)
hsa-mir-181a	DLBCL tissue samples	(23)
	DLBCL tissue samples	(63)
hsa-mir-217	DLBCL tissue samples	(23)
	DLBCL tissue samples	(64)
hsa-mir-361	DLBCL tissue samples	(23)
	The expression profile data of GSE31377	(65)
	The human lymphoma cell lines Jurkat, Hut102, U937 and Raji	
hsa-mir-363	DLBCL tissue samples	(23)
	Cryopreserved DLBCL tissues	(66)
hsa-let-7f	DLBCL tissue samples	(40)
	Frozen DLBCL tissues	(67)
hsa-mir-20b	Immunophenotype classified DLBCL cell lines	(34)
	DLBCL tissue samples	(68)
hsa-mir-26a	Immunophenotype classified DLBCL cell lines	(34)
	DLBCL cell lines	(69)
hsa-mir-26b	DLBCL tissue samples	(40)
	DLBCL serum samples	(70)
hsa-mir-29b	DLBCL tissue samples	(40)
	DLBCL tissue samples	(71)
hsa-mir-29c	DLBCL serum samples	(46)
	DLBCL serum samples	(72)
hsa-mir-125b	DLBCL tissue samples	(40)
	DLBCL tissue samples	(73)
hsa-mir-145	DLBCL tissue samples	(23)
	DLBCL tissue samples	(74)
hsa-mir-223	DLBCL tissue samples	(40)
	DLBCL tissue samples	(75)
hsa-mir-301a	DLBCL tissue samples	(23)
	DLBCL tissue samples	(36)
hsa-mir-23a	DLBCL tissue samples	(71)
	DLBCL tissue samples	(76)
hsa-mir-23b	DLBCL tissue samples	(71)
	Tonsillar lymphocytes	(38)
hsa-mir-27a	DLBCL tissue samples	(23)
	Tonsillar lymphocytes	(38)
hsa-mir-27b	DLBCL tissue samples	(23)
	DLBCL tissue samples	(77)

References

34. Culpin RE, Proctor SJ, Angus B, et al. A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines. *Int J Oncol* 2010;37:367-76.
35. Culpin RE, Sieniawski M, Proctor SJ, et al. MicroRNAs are suitable for assessment as biomarkers from formalin-fixed paraffin-embedded tissue, and miR-24 represents an appropriate reference microRNA for diffuse large B-cell lymphoma studies. *J Clin Pathol* 2013;66:249-52.
36. Roehle A, Hoefig KP, Repsilber D, et al. MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. *Br J Haematol* 2008;142:732-44.
37. Lawrie CH, Soneji S, Marafioti T, et al. MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. *Int J Cancer* 2007;121:1156-61.
38. Malumbres R, Sarosiek KA, Cubedo E, et al. Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. *Blood* 2009;113:3754-64.
39. Akao Y, Nakagawa Y, Kitade Y, et al. Downregulation of microRNAs-143 and -145 in B-cell malignancies. *Cancer Sci* 2007;98:1914-20.
40. Di Lisio L, Sánchez-Beato M, Gómez-López G, et al. MicroRNA signatures in B-cell lymphomas. *Blood Cancer J* 2012;2:e57.
41. Zhong H, Xu L, Zhong JH, et al. Clinical and prognostic significance of miR-155 and miR-146a expression levels in formalin-fixed/paraffin-embedded tissue of patients with diffuse large B-cell lymphoma. *Exp Ther Med* 2012;3:763-70.
42. Wu PY, Zhang XD, Zhu J, et al. Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone. *Hum Pathol* 2014;45:1664-73.
43. Veryaskina YA, Titov SE, Kovynev IB, et al. MicroRNA Expression Profiling of Diffuse Large B-Cell Lymphoma. *Mol Biol (Mosk)* 2023;57:492-500.
44. Munch-Petersen HD, Ralfkiaer U, Sjö LD, et al. Differential expression of miR-155 and miR-21 in tumor and stroma cells in diffuse large B-cell lymphoma. *Appl Immunohistochem Mol Morphol* 2015;23:188-95.
45. Kluiver J, Poppema S, de Jong D, et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. *J Pathol* 2005;207:243-9.
46. Fang C, Zhu DX, Dong HJ, et al. Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma. *Ann Hematol* 2012;91:553-9.
47. Sewastianik T, Straubhaar JR, Zhao JJ, et al. miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms. *Blood* 2021;137:1905-19.
48. Inomata M, Tagawa H, Guo YM, et al. MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. *Blood* 2009;113:396-402.
49. Larrabeiti-Etxebarria A, Bilbao-Aldaiturriaga N, Arzuaga-Mendez J, et al. microRNA sequencing for biomarker detection in the diagnosis, classification and prognosis of Diffuse Large B Cell Lymphoma. *Sci Rep* 2023;13:12159.
50. Alencar AJ, Malumbres R, Kozloski GA, et al. MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. *Clin Cancer Res* 2011;17:4125-35.
51. Troppan K, Wenzl K, Pichler M, et al. miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patients. *Int J Mol Sci* 2015;16:18077-95.
52. Yan S, Jia C, Quan L, et al. Significance of the microRNA-17-92 gene cluster expressed in B-cell non-Hodgkin's lymphoma. *Mol Med Rep* 2019;20:2459-67.
53. Go H, Jang JY, Kim PJ, et al. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma. *Oncotarget* 2015;6:15035-49.
54. Fassina A, Marino F, Siri M, et al. The miR-17-92 microRNA cluster: a novel diagnostic tool in large B-cell malignancies. *Lab Invest* 2012;92:1574-82.
55. Montes-Moreno S, Martinez N, Sanchez-Espiridión B, et al. miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. *Blood* 2011;118:1034-40.
56. Lim EL, Trinh DL, Scott DW, et al. Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients. *Genome Biol* 2015;16:18.
57. He M, Gao L, Zhang S, et al. Prognostic significance of miR-34a and its target proteins of FOXP1, p53, and BCL2 in gastric MALT lymphoma and DLBCL. *Gastric Cancer* 2014;17:431-41.
58. Wang J, Shang S, Li J, et al. PD-L1 and miR-34a are Prognostic Factors for Primary Gastric Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP. *Cancer Manag Res* 2020;12:4999-5008.
59. Voropaeva EN, Pospelova TI, Orlov YL, et al. The

- Methylation of the p53 Targets the Genes MIR-203, MIR-129-2, MIR-34A and MIR-34B/C in the Tumor Tissue of Diffuse Large B-Cell Lymphoma. *Genes (Basel)* 2022;13:1401.
60. Nordmo C, Glehr G, Altenbuchinger M, et al. Identification of a miRNA based model to detect prognostic subgroups in patients with aggressive B-cell lymphoma. *Leuk Lymphoma* 2021;62:1107-15.
 61. Ding L, Zhang Y, Han L, et al. Activating and sustaining c-Myc by depletion of miR-144/451 gene locus contributes to B-lymphomagenesis. *Oncogene* 2018;37:1293-307.
 62. Leivonen SK, Icaý K, Jäntti K, et al. MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma. *Blood Cancer J* 2017;7:654.
 63. Kozloski GA, Jiang X, Bhatt S, et al. miR-181a negatively regulates NF- κ B signaling and affects activated B-cell-like diffuse large B-cell lymphoma pathogenesis. *Blood* 2016;127:2856-66.
 64. de Yébenes VG, Bartolomé-Izquierdo N, Nogales-Cadenas R, et al. miR-217 is an oncogene that enhances the germinal center reaction. *Blood* 2014;124:229-39.
 65. Zhou H, Tang H, Li N, et al. MicroRNA-361-3p Inhibit the Progression of Lymphoma by the Wnt/ β -Catenin Signaling Pathway. *Cancer Manag Res* 2020;12:12375-84.
 66. Zhou W, Xu Y, Zhang J, et al. MiRNA-363-3p/DUSP10/JNK axis mediates chemoresistance by enhancing DNA damage repair in diffuse large B-cell lymphoma. *Leukemia* 2022;36:1861-9.
 67. Nie K, Zhang T, Allawi H, et al. Epigenetic down-regulation of the tumor suppressor gene PRDM1/Blimp-1 in diffuse large B cell lymphomas: a potential role of the microRNA let-7. *Am J Pathol* 2010;177:1470-9.
 68. Borges NM, do Vale Elias M, Fook-Alves VL, et al. Angiomirs expression profiling in diffuse large B-Cell lymphoma. *Oncotarget* 2016;7:4806-16.
 69. Farina FM, Inguscio A, Kunderfranco P, et al. MicroRNA-26a/cyclin-dependent kinase 5 axis controls proliferation, apoptosis and in vivo tumor growth of diffuse large B-cell lymphoma cell lines. *Cell Death Dis* 2017;8:e2890.
 70. Metwally AM, Kasem AAHM, Youssif MI, et al. Lymphocyte to monocyte ratio predicts survival and is epigenetically linked to miR-222-3p and miR-26b-5p in diffuse large B cell lymphoma. *Sci Rep* 2023;13:4899.
 71. Lenze D, Leoncini L, Hummel M, et al. The different epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma. *Leukemia* 2011;25:1869-76.
 72. Meng Y, Quan L, Liu A. Identification of key microRNAs associated with diffuse large B-cell lymphoma by analyzing serum microRNA expressions. *Gene* 2018;642:205-11.
 73. Kim SW, Ramasamy K, Bouamar H, et al. MicroRNAs miR-125a and miR-125b constitutively activate the NF- κ B pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). *Proc Natl Acad Sci U S A* 2012;109:7865-70.
 74. Gao Y, Ding X. miR-145-5p exerts anti-tumor effects in diffuse large B-cell lymphoma by regulating S1PR1/STAT3/AKT pathway. *Leuk Lymphoma* 2021;62:1884-91.
 75. Yao S, Guo T, Zhang F, et al. Fbw7 Inhibits the Progression of Activated B-Cell Like Diffuse Large B-Cell Lymphoma by Targeting the Positive Feedback Loop of the LDHA/lactate/miR-223 Axis. *Front Oncol* 2022;12:842356.
 76. Wang WL, Yang C, Han XL, et al. MicroRNA-23a expression in paraffin-embedded specimen correlates with overall survival of diffuse large B-cell lymphoma. *Med Oncol* 2014;31:919.
 77. Jia YJ, Liu ZB, Wang WG, et al. HDAC6 regulates microRNA-27b that suppresses proliferation, promotes apoptosis and target MET in diffuse large B-cell lymphoma. *Leukemia* 2018;32:703-11.